Cargando…

Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1

BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and b...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchanan, Daniel D., Stewart, Jenna R., Clendenning, Mark, Rosty, Christophe, Mahmood, Khalid, Pope, Bernard J., Jenkins, Mark A., Hopper, John L., Southey, Melissa C., Macrae, Finlay A., Winship, Ingrid M., Win, Aung Ko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943186/
https://www.ncbi.nlm.nih.gov/pubmed/29120461
http://dx.doi.org/10.1038/gim.2017.185
_version_ 1783321579390763008
author Buchanan, Daniel D.
Stewart, Jenna R.
Clendenning, Mark
Rosty, Christophe
Mahmood, Khalid
Pope, Bernard J.
Jenkins, Mark A.
Hopper, John L.
Southey, Melissa C.
Macrae, Finlay A.
Winship, Ingrid M.
Win, Aung Ko
author_facet Buchanan, Daniel D.
Stewart, Jenna R.
Clendenning, Mark
Rosty, Christophe
Mahmood, Khalid
Pope, Bernard J.
Jenkins, Mark A.
Hopper, John L.
Southey, Melissa C.
Macrae, Finlay A.
Winship, Ingrid M.
Win, Aung Ko
author_sort Buchanan, Daniel D.
collection PubMed
description BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and by genotyping 669 population-based CRC cases diagnosed <60 years of age from the Australasian Colorectal Cancer Family Registry. We estimated the age-specific cumulative risks (penetrance) using a modified segregation analysis. RESULTS: We observed 67 CRCs (mean age at diagnosis=50.2 (standard deviation [SD]=13.8) years) among 364 first- and second- degree relatives from 41 POLE families and 6 CRCs (mean age at diagnosis=39.7 (SD=6.83) years) among 69 relatives from 9 POLD1 families. We estimated risks of CRC to age 70 years (95% confidence interval [CI]) for males and females, respectively, to be: 40%(26%–57%) and 32%(20%–47%) for POLE mutation carriers; and 63%(15%–99%) and 52%(11%–99%) for POLD1 mutation carriers. CONCLUSION: CRC risks for POLE mutation carriers are sufficiently high warranting consideration of annual colonoscopy screening and management guidelines comparable to Lynch syndrome. Refinement of estimates of CRC risk for POLD1 carriers is needed, however, clinical management recommendations could follow those suggested for POLE carriers.
format Online
Article
Text
id pubmed-5943186
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-59431862018-09-21 Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 Buchanan, Daniel D. Stewart, Jenna R. Clendenning, Mark Rosty, Christophe Mahmood, Khalid Pope, Bernard J. Jenkins, Mark A. Hopper, John L. Southey, Melissa C. Macrae, Finlay A. Winship, Ingrid M. Win, Aung Ko Genet Med Article BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and by genotyping 669 population-based CRC cases diagnosed <60 years of age from the Australasian Colorectal Cancer Family Registry. We estimated the age-specific cumulative risks (penetrance) using a modified segregation analysis. RESULTS: We observed 67 CRCs (mean age at diagnosis=50.2 (standard deviation [SD]=13.8) years) among 364 first- and second- degree relatives from 41 POLE families and 6 CRCs (mean age at diagnosis=39.7 (SD=6.83) years) among 69 relatives from 9 POLD1 families. We estimated risks of CRC to age 70 years (95% confidence interval [CI]) for males and females, respectively, to be: 40%(26%–57%) and 32%(20%–47%) for POLE mutation carriers; and 63%(15%–99%) and 52%(11%–99%) for POLD1 mutation carriers. CONCLUSION: CRC risks for POLE mutation carriers are sufficiently high warranting consideration of annual colonoscopy screening and management guidelines comparable to Lynch syndrome. Refinement of estimates of CRC risk for POLD1 carriers is needed, however, clinical management recommendations could follow those suggested for POLE carriers. 2017-11-09 2018-08 /pmc/articles/PMC5943186/ /pubmed/29120461 http://dx.doi.org/10.1038/gim.2017.185 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Buchanan, Daniel D.
Stewart, Jenna R.
Clendenning, Mark
Rosty, Christophe
Mahmood, Khalid
Pope, Bernard J.
Jenkins, Mark A.
Hopper, John L.
Southey, Melissa C.
Macrae, Finlay A.
Winship, Ingrid M.
Win, Aung Ko
Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title_full Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title_fullStr Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title_full_unstemmed Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title_short Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
title_sort risk of colorectal cancer for carriers of a germline mutation in pole or pold1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943186/
https://www.ncbi.nlm.nih.gov/pubmed/29120461
http://dx.doi.org/10.1038/gim.2017.185
work_keys_str_mv AT buchanandanield riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT stewartjennar riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT clendenningmark riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT rostychristophe riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT mahmoodkhalid riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT popebernardj riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT jenkinsmarka riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT hopperjohnl riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT southeymelissac riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT macraefinlaya riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT winshipingridm riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1
AT winaungko riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1